{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:06:02Z","timestamp":1754154362277,"version":"3.41.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"DOI":"10.7759\/cureus.88645","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T08:39:43Z","timestamp":1753346383000},"source":"Crossref","is-referenced-by-count":0,"title":["Lung Function Changes and Connective Tissue Growth Factor Expression in Idiopathic Pulmonary Fibrosis, Other Progressive Fibrosing Interstitial Lung Diseases, and Post-COVID Fibrosis"],"prefix":"10.7759","author":[{"given":"Elene","family":"Sherozia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamuna","family":"Kakhniashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nino","family":"Tabagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Gotua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu G","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al.. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018, 198:e44-68. 10.1164\/rccm.201807-1255ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan SK","year":"2023","unstructured":"Rajan SK, Cottin V, Dhar R, et al.. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023, 61:2103187. 10.1183\/13993003.03187-2021","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek M","year":"2019","unstructured":"Wijsenbeek M, Kreuter M, Olson A, et al.. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019, 35:2015-24. 10.1080\/03007995.2019.1647040","journal-title":"Curr Med Res Opin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0073-2018","article-title":"Role of imaging in progressive-fibrosing interstitial lung diseases","volume":"27","author":"Walsh SL","year":"2018","unstructured":"Walsh SL, Devaraj A, Enghelmayer JI, et al.. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018, 27:180073. 10.1183\/16000617.0073-2018","journal-title":"Eur Respir Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu G","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al.. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022, 205:e18-47. 10.1164\/rccm.202202-0399ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00000713","article-title":"The role of infection in the pathogenesis of idiopathic pulmonary fibrosis","volume":"22","author":"Molyneaux PL","year":"2013","unstructured":"Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. 2013, 22:376-81. 10.1183\/09059180.00000713","journal-title":"Eur Respir Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00069307","article-title":"Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?","volume":"30","author":"Maher TM","year":"2007","unstructured":"Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J. 2007, 30:835-9. 10.1183\/09031936.00069307","journal-title":"Eur Respir J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0077-2018","article-title":"The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype","volume":"27","author":"Olson AL","year":"2018","unstructured":"Olson AL, Gifford AH, Inase N, Fern\u00e1ndez P\u00e9rez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018, 27:180077. 10.1183\/16000617.0077-2018","journal-title":"Eur Respir Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30222-8","article-title":"Pulmonary fibrosis secondary to COVID- 19: a call to arms?","volume":"8","author":"Spagnolo P","year":"2020","unstructured":"Spagnolo P, Balestro E, Aliberti S, et al.. Pulmonary fibrosis secondary to COVID- 19: a call to arms?. Lancet Respir Med. 2020, 8:750-2. 10.1016\/s2213-2600(20)30222-8","journal-title":"Lancet Respir Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcaa255","article-title":"Post-COVID-19 pneumonia pulmonary fibrosis","volume":"113","author":"Tale S","year":"2020","unstructured":"Tale S, Ghosh S, Meitei SP, Kolli M, Garbhapu AK, Pudi S. Post-COVID-19 pneumonia pulmonary fibrosis. QJM. 2020, 113:837-8. 10.1093\/qjmed\/hcaa255","journal-title":"QJM"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04015-2020","article-title":"Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life","volume":"58","author":"Anastasio F","year":"2021","unstructured":"Anastasio F, Barbuto S, Scarnecchia E, et al.. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life. Eur Respir J. 2021, 58:2004015. 10.1183\/13993003.04015-2020","journal-title":"Eur Respir J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03263-2020","article-title":"Caution in interpretation of abnormal carbon monoxide diffusion capacity in COVID-19 patients","volume":"57","author":"Chapman DG","year":"2021","unstructured":"Chapman DG, Badal T, King GG, Thamrin C. Caution in interpretation of abnormal carbon monoxide diffusion capacity in COVID-19 patients. Eur Respir J. 2021, 57:2003263. 10.1183\/13993003.03263-2020","journal-title":"Eur Respir J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03448-2020","article-title":"Dyspnoea, lung function and CT findings 3\u2005months after hospital admission for COVID-19","volume":"57","author":"Lerum TV","year":"2021","unstructured":"Lerum TV, Aal\u00f8kken TM, Br\u00f8nstad E, et al.. Dyspnoea, lung function and CT findings 3\u2005months after hospital admission for COVID-19. Eur Respir J. 2021, 57:2003448. 10.1183\/13993003.03448-2020","journal-title":"Eur Respir J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03677-2020","article-title":"Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up","volume":"58","author":"Qin W","year":"2021","unstructured":"Qin W, Chen S, Zhang Y, et al.. Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up. Eur Respir J. 2021, 58:2003677. 10.1183\/13993003.03677-2020","journal-title":"Eur Respir J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2024.89634","article-title":"Identification, course, and management of\u00a0progressive pulmonary fibrosis","volume":"30","author":"Podolanczuk AJ","year":"2024","unstructured":"Podolanczuk AJ, Fern\u00e1ndez Per\u00e9z ER. Identification, course, and management of\u00a0progressive pulmonary fibrosis. Am J Manag Care. 2024, 30:S122-30. 10.37765\/ajmc.2024.89634","journal-title":"Am J Manag Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.680997","article-title":"Biomarkers in progressive fibrosing interstitial lung disease: optimizing diagnosis, prognosis, and treatment response","volume":"8","author":"Bowman WS","year":"2021","unstructured":"Bowman WS, Echt GA, Oldham JM. Biomarkers in progressive fibrosing interstitial lung disease: optimizing diagnosis, prognosis, and treatment response. Front Med (Lausanne). 2021, 8:680997. 10.3389\/fmed.2021.680997","journal-title":"Front Med (Lausanne)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066354","article-title":"Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis","volume":"377","author":"Liu GY","year":"2022","unstructured":"Liu GY, Budinger GR, Dematte JE. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ. 2022, 377:e066354. 10.1136\/bmj-2021-066354","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0071-2018","article-title":"Acute exacerbations of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Kolb M","year":"2018","unstructured":"Kolb M, Bondue B, Pesci A, et al.. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018, 27:180071. 10.1183\/16000617.0071-2018","journal-title":"Eur Respir Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0074-2018","article-title":"Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence","volume":"27","author":"Richeldi L","year":"2018","unstructured":"Richeldi L, Varone F, Bergna M, et al.. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018, 27:180074. 10.1183\/16000617.0074-2018","journal-title":"Eur Respir Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.08.008","article-title":"Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF)","volume":"412","author":"Kono M","year":"2011","unstructured":"Kono M, Nakamura Y, Suda T, et al.. Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta. 2011, 412:2211-5. 10.1016\/j.cca.2011.08.008","journal-title":"Clin Chim Acta"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/art.27382","article-title":"Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis","volume":"62","author":"Sonnylal S","year":"2010","unstructured":"Sonnylal S, Shi-Wen X, Leoni P, et al.. Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 2010, 62:1523-32. 10.1002\/art.27382","journal-title":"Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116064","article-title":"Connective tissue growth factor in idiopathic pulmonary fibrosis: breaking the bridge","volume":"23","author":"Effendi WI","year":"2022","unstructured":"Effendi WI, Nagano T. Connective tissue growth factor in idiopathic pulmonary fibrosis: breaking the bridge. Int J Mol Sci. 2022, 23:6064. 10.3390\/ijms23116064","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw339","article-title":"Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis","volume":"109","author":"Bickelhaupt S","year":"2017","unstructured":"Bickelhaupt S, Erbel C, Timke C, et al.. Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis. J Natl Cancer Inst. 2017, 109:10.1093\/jnci\/djw339","journal-title":"J Natl Cancer Inst"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.8693","article-title":"Pamrevlumab for idiopathic pulmonary fibrosis: The ZEPHYRUS-1 randomized clinical trial","volume":"332","author":"Raghu G","year":"2024","unstructured":"Raghu G, Richeldi L, Fern\u00e1ndez P\u00e9rez ER, et al.. Pamrevlumab for idiopathic pulmonary fibrosis: The ZEPHYRUS-1 randomized clinical trial. JAMA. 2024, 332:380-9. 10.1001\/jama.2024.8693","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/326337-lung-function-changes-and-connective-tissue-growth-factor-expression-in-idiopathic-pulmonary-fibrosis-other-progressive-fibrosing-interstitial-lung-diseases-and-post-covid-fibrosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T08:39:44Z","timestamp":1753346384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/326337-lung-function-changes-and-connective-tissue-growth-factor-expression-in-idiopathic-pulmonary-fibrosis-other-progressive-fibrosing-interstitial-lung-diseases-and-post-covid-fibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.88645","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}